Recombinant Proteins

Antitumor agent-81 (compound 5a) is a low cytotoxicity P62-RNF168 agonist that enhances the interaction between P62 and RNF168.

Tisotumab vedotin is an ADC targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor MMAE.

Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an anti EGFR monoclonal antibody (Depatuxizumab) and the cytotoxic agent Monometl auristatin E (MMAE).

TfR-1-IN-1 (compound C4) is an inhibitor of transferrin receptor 1 (TfR-1) with anticancer activity.

Fumagilin-105 is an autophagy targeting chimera (AUTOTAC) that induces p62 self-oligomerization with DC50 values of 0.7 μM for MetAP2 in HEK293 cells.

ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab.

Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma.

Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells.

Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 ).

Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 , via a cleavable linker.

Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker.

Farletuzumab ecteribulin (MORAb-202) is an ADC, consisting of the humanized anti-human FRA antibody Farletuzumab conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin.

Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC).

Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb joined to an auristatin microtubule inhibitor payload, auristatin-0101, by a cleavable valine-citrulline (vc)-based linker.

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monometl vedotin.

YTK-105 is a ligand of p62-ZZ domain.

BMMP is an anti- HIV-1 agent and hnRNP M modulator.

EAD1 trihydrochloride is a Chloroquine analog with anticancer activity.

CDH11-IN-1 is a CDH11 inhibitor.

BAS00093476 is an E-cadherin inhibitor.

BAS00602705 is an E-cadherin inhibitor.

Pitstop 2c is a clathrin terminal domain inhibitor with an IC 50 of 1.8 μM.

Type IV collagen peptide acetate is a cell-binding ligand peptide derived from type IV collagen.

CAST-calpain-2 stabilizer-1 is a blood-brain barrier permeable stabilizer of CAST-calpain-2 interaction.